moneyheap
DYN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Dyne Therapeutics, Inc. Common Stock (DYN) stock moving?
DYN closed at $17.92 on Nov 10, down 3.7% from $18.62 on Nov 9, on volume of 2.39M shares versus 3.86M the day before. The stock has traded between $15.3 and $19.00 over the last month, with the $19.00 high set on Nov 4 and again on Nov 9. The Q3 report on Nov 5 showed a loss of $1.06 per share against a $0.92 estimate, and the stock fell 6.4% that day to $17.36 before recovering. Oppenheimer's Oct 28 downgrade to Perform with a $15 target sits below the current price. The main pending catalyst is the z-rostudirsen BLA under FDA priority review, with a PDUFA date of Jan 21, 2027 and a potential launch in Q1 2027. The z-basivarsen DM1 registrational expansion cohort topline is also due in Q1 2027. PepGen's positive Phase 2 DM1 data on Nov 10 may validate the DM1 field but adds competition, and DYN's decline that day is consistent with that read-across.
News behind the analysis
- PepGen Stock Doubles in One Session - Here's WhyPepGen reported positive Phase 2 results for PGN-EDODM1 in DM1, a disease also targeted by Dyne's z-basivarsen. DYN closed down 3.7% the same day.
- Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsThe BLA for z-rostudirsen in exon 51 DMD is under FDA priority review with a PDUFA date of Jan 21, 2027. Topline ACHIEVE registrational expansion cohort data for z-basivarsen in DM1 are expected in Q1 2027.
- Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) EstimateDyne reported a third-quarter loss of $1.06 per share, wider than the $0.92 consensus estimate.
- Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15Oppenheimer cut DYN from Outperform to Perform and set a $15 price target, below the recent trading range.
- Oppenheimer Downgrades Dyne Therapeutics to PerformOppenheimer moved Dyne from Outperform to Perform with a $15 price target.
About Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics is a Waltham, Massachusetts biotech developing treatments for genetic neuromuscular diseases such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and FSHD. Its FORCE platform attaches genetic medicines to an antibody fragment that helps carry them into muscle. Its lead DMD drug, z-rostudirsen (DYNE-251), is under FDA priority review, with a decision targeted for January 21, 2027.
How it makes money
Dyne has no approved products yet and reported no revenue in 2026. It pays for research and trials with money raised from investors, including about $405 million from a stock sale in July 2026. It had about $1.1 billion in cash and investments as of September 30, 2026, and net losses of about $190 million a quarter. If its drugs are approved, future revenue would come from product sales.
What usually moves DYN
- FDA decision on z-rostudirsen for DMD (target Jan 2027)
- Clinical data for z-basivarsen (DYNE-101) in DM1
- Competitor trial results, e.g. Avidity in DM1 and DMD
- Cash burn and share sales that dilute existing holders
- Sentiment toward the biotech sector overall